创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

叶静, 肖婷婷, 王雪婷, 朱云颖, 杨凯, 肖永红. 新型抗菌药物研究进展与临床应用[J]. 药学进展, 2021, 45(6): 403-412.
引用本文: 叶静, 肖婷婷, 王雪婷, 朱云颖, 杨凯, 肖永红. 新型抗菌药物研究进展与临床应用[J]. 药学进展, 2021, 45(6): 403-412.
YE Jing, XIAO Tingting, WANG Xueting, ZHU Yunying, YANG Kai, XIAO Yonghong. Research Progress and Clinical Application of New Antibiotics[J]. Progress in Pharmaceutical Sciences, 2021, 45(6): 403-412.
Citation: YE Jing, XIAO Tingting, WANG Xueting, ZHU Yunying, YANG Kai, XIAO Yonghong. Research Progress and Clinical Application of New Antibiotics[J]. Progress in Pharmaceutical Sciences, 2021, 45(6): 403-412.

新型抗菌药物研究进展与临床应用

Research Progress and Clinical Application of New Antibiotics

  • 摘要: 开发新型抗菌药物成为世界卫生组织(WHO)应对耐药细菌感染的主要策略。在有关新药研发政策激励下,新型抗菌药物的研究与开发得到新药研发机构的重视。近10年来,已有各种新型抗菌药物上市或处于不同开发阶段。简介全球已上市的主要用于治疗耐药菌感染药物,包括新型β-内酰胺酶抑制剂复方、头孢菌素、糖肽类、四环素类、唑烷酮类等,对其相关药理学、临床研究、安全性等重点介绍,以期为相关研究与临床应用提供参考。

     

    Abstract: The research and development of new antibiotics to deal with drug-resistant bacterial infection has become the main strategy of World Health Organization. Under the incentive of new drug R&D policies, the research and development of new antibiotics has attracted the attention of new drug research institutions. During the recent 10 years, quite a few innovative antibacterial drugs have been launched to the market or under development at different stages. In this review, the main drugs in the global market for the treatment of drug-resistant bacterial infections are introduced, including new β-lactamase inhibitor, cephalosporins, glycopeptides, tetracyclines, oxazolidinones, etc., with particular attention to their related pharmacology, clinical research, and safety, aiming to provide reference for the related research and clinical application.

     

/

返回文章
返回